Compare Becton Dickinson and Co (BDX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Texas Instruments Incorporated — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Texas Instruments Incorporated trades at $308 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 6.7× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | TXN | |
|---|---|---|
Market Cap | $41.51B | $278.08B |
Sector | Health | Technology |
52-Week High | $185.39 | $332.35 |
52-Week Low | $135.49 | $153.33 |
Enterprise Value | $57.97B | $287.03B |
Dividend Yield | 2.79% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Texas Instruments (TXN) trades at $298.57, down 4.15% over the past day, with technical indicators showing a bearish trend. The company reported mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with revenue of $17.68 billion in 2025. Analyst sentiment is positive, with a consensus price target of $317.20 and 48% buy ratings. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
Outlook: TXN benefits from AI infrastructure growth and operational leverage, but faces risks from high valuation multiples and competitive pressures. The stock offers potential upside to the consensus target, supported by solid profitability and dividend payments, though investors should monitor debt levels and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
